Literature DB >> 1971852

Heterogeneity of clinical severity and molecular lesions in Aicardi syndrome.

J A Neidich1, R L Nussbaum, R J Packer, B S Emanuel, J M Puck.   

Abstract

All patients with Aicardi syndrome are female or have a 47,XXY karyotype. This finding, along with a report of an Aicardi syndrome patient with an Xp22/autosome translocation, led to the hypothesis that Aicardi syndrome might be caused by an X-linked dominant, male-lethal mutation on the short arm of the X chromosome. To study this hypothesis, we investigated X chromosome inactivation patterns in peripheral lymphocytes from seven patients. We used two methods: methylation-sensitive restriction enzyme analysis and segregation of the active X chromosome in somatic cell hybrids. We found that three of seven cytogenetically normal girls with Aicardi syndrome had profoundly skewed X-inactivation in their lymphocytes, supporting the concept that Aicardi syndrome is X linked. Three of the five girls with the greatest degree of psychomotor retardation and the poorest seizure control had skewed X-inactivation. In contrast, the two highest-functioning children had random X-inactivation. We screened DNA using eight polymorphic probes from the Xp22 region but were unable to identify a deletion in any of the seven patients. Nonrandom X-inactivation in lymphocytes and possibly other tissues in some, but not all, patients with Aicardi syndrome may reflect heterogeneity of their molecular lesions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971852     DOI: 10.1016/s0022-3476(05)80649-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

1.  Monozygotic twins discordant for Aicardi syndrome.

Authors:  T Costa; W Greer; G Rysiecki; J R Buncic; P N Ray
Journal:  J Med Genet       Date:  1997-08       Impact factor: 6.318

2.  Laterality of brain and ocular lesions in Aicardi syndrome.

Authors:  Michelle T Cabrera; Bryan J Winn; Travis Porco; Zoe Strominger; A James Barkovich; Creig S Hoyt; Mari Wakahiro; Elliott H Sherr
Journal:  Pediatr Neurol       Date:  2011-09       Impact factor: 3.372

3.  Aicardi syndrome--the elusive mild case.

Authors:  A V Menezes; R W Enzenauer; J R Buncic
Journal:  Br J Ophthalmol       Date:  1994-06       Impact factor: 4.638

4.  Unlayered polymicrogyria and agenesis of the corpus callosum: a relevant association?

Authors:  T Billette de Villemeur; C Chiron; O Robain
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

5.  EEG recognition of holoprosencephaly and Aicardi syndrome.

Authors:  K N Shah; S Rajadhyaksha; V S Shah; M Wakde
Journal:  Indian J Pediatr       Date:  1992 Jan-Feb       Impact factor: 1.967

6.  Role of ocular involvement in the prediction of visual development and clinical prognosis in Aicardi syndrome.

Authors:  A V Menezes; T L Lewis; J R Buncic
Journal:  Br J Ophthalmol       Date:  1996-09       Impact factor: 4.638

7.  A genome-wide screen for copy number alterations in Aicardi syndrome.

Authors:  Xiaoling Wang; V Reid Sutton; Tanya N Eble; Richard Alan Lewis; Preethi Gunaratne; Ankita Patel; Ignatia B Van den Veyver
Journal:  Am J Med Genet A       Date:  2009-10       Impact factor: 2.802

8.  Non-random X chromosome inactivation in Aicardi syndrome.

Authors:  Tanya N Eble; V Reid Sutton; Haleh Sangi-Haghpeykar; Xiaoling Wang; Weihong Jin; Richard A Lewis; Ping Fang; Ignatia B Van den Veyver
Journal:  Hum Genet       Date:  2009-01-01       Impact factor: 4.132

9.  X chromosome inactivation patterns correlate with fetal-placental anatomy in monozygotic twin pairs: implications for immune relatedness and concordance for autoimmunity.

Authors:  V Trejo; C Derom; R Vlietinck; W Ollier; A Silman; G Ebers; R Derom; P K Gregersen
Journal:  Mol Med       Date:  1994-11       Impact factor: 6.354

10.  Palliative epilepsy surgery in Aicardi syndrome: a case series and review of literature.

Authors:  Aimen S Kasasbeh; Christina A Gurnett; Matthew D Smyth
Journal:  Childs Nerv Syst       Date:  2013-08-16       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.